[
  {
    "ts": "2025-09-25T13:00:00+00:00",
    "headline": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
    "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
    "url": "https://finance.yahoo.com/news/dr-robert-lenz-joins-unlearn-130000906.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "60fe7e8d-6801-3212-b33a-f8d681c09075",
      "content": {
        "id": "60fe7e8d-6801-3212-b33a-f8d681c09075",
        "contentType": "STORY",
        "title": "Dr. Robert Lenz Joins Unlearn as Strategic Advisor",
        "description": "",
        "summary": "SAN FRANCISCO, September 25, 2025--Unlearn, a leader in AI solutions for clinical trials, welcomed Dr. Robert Lenz as a strategic advisor to advise Unlearn as they expand partnerships.",
        "pubDate": "2025-09-25T13:00:00Z",
        "displayTime": "2025-09-25T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/5a61278c9f7e47e58f3f3a4f317d3c4c",
          "originalWidth": 1024,
          "originalHeight": 512,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/UIvqBtmca36NdXY0rBbdlA--~B/aD01MTI7dz0xMDI0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/5a61278c9f7e47e58f3f3a4f317d3c4c.cf.webp",
              "width": 1024,
              "height": 512,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/zUY5.sideP307fltaWi6Eg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/5a61278c9f7e47e58f3f3a4f317d3c4c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/dr-robert-lenz-joins-unlearn-130000906.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/dr-robert-lenz-joins-unlearn-130000906.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T11:01:00+00:00",
    "headline": "QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published",
    "summary": "AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii",
    "url": "https://finance.yahoo.com/news/qulipta-atogepant-now-publicly-reimbursed-110100590.html",
    "source": "CNW Group",
    "provider": "yfinance",
    "raw": {
      "id": "69882acd-bec8-3fca-b131-30920fb09700",
      "content": {
        "id": "69882acd-bec8-3fca-b131-30920fb09700",
        "contentType": "STORY",
        "title": "QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) announced today that the RAMQ has listed QULIPTA® in their formulary for the prevention of chronic migraine and episodic migraine.i This will be followed by reimbursement by private plans, mimicking the public formulary. The Institut national d'excellence en santé et en services sociaux (INESSS) previously published a positive recommendation for the public listing of QULIPTA® (atogepant) in the treatment of chronic migraine in adults on July 2, 2025.ii",
        "pubDate": "2025-09-25T11:01:00Z",
        "displayTime": "2025-09-25T11:01:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/cnwgroup.com/6dbf9b1cdd69f27d6b25b1d6a682ac51",
          "originalWidth": 400,
          "originalHeight": 70,
          "caption": "AbbVie logo (CNW Group/AbbVie Canada)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fE3zreryLpqlG4xfE1iXgA--~B/aD03MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/cnwgroup.com/6dbf9b1cdd69f27d6b25b1d6a682ac51.cf.webp",
              "width": 400,
              "height": 70,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_P3E_WxvldTKUPf5XXatRg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/cnwgroup.com/6dbf9b1cdd69f27d6b25b1d6a682ac51.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "CNW Group",
          "url": "http://www.newswire.ca/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/qulipta-atogepant-now-publicly-reimbursed-110100590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/qulipta-atogepant-now-publicly-reimbursed-110100590.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T09:00:00+00:00",
    "headline": "3 Top Dividend Stocks to Buy and Hold Forever",
    "summary": "These blue chip dividend stocks offer both income and growth potential.",
    "url": "https://www.fool.com/investing/2025/09/25/3-top-dividend-stocks-to-buy-and-hold-forever/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ed5fa360-edb4-318a-a4bc-8fa1d08675bc",
      "content": {
        "id": "ed5fa360-edb4-318a-a4bc-8fa1d08675bc",
        "contentType": "STORY",
        "title": "3 Top Dividend Stocks to Buy and Hold Forever",
        "description": "",
        "summary": "These blue chip dividend stocks offer both income and growth potential.",
        "pubDate": "2025-09-25T09:00:00Z",
        "displayTime": "2025-09-25T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/8b518bfab66bd6a0630cf5a9d6236d20",
          "originalWidth": 1400,
          "originalHeight": 933,
          "caption": "A roll of U.S. currency next to a sticky pad that reads dividends.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/qQq58WhsB9k6BBCZiIb3_w--~B/aD05MzM7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/8b518bfab66bd6a0630cf5a9d6236d20.cf.webp",
              "width": 1400,
              "height": 933,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7gY6e2CMup5VyvuaupoSNw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/8b518bfab66bd6a0630cf5a9d6236d20.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/25/3-top-dividend-stocks-to-buy-and-hold-forever/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-top-dividend-stocks-buy-090000837.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "TNC"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T09:00:00+00:00",
    "headline": "Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai",
    "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.",
    "url": "https://finance.yahoo.com/news/allergan-aesthetics-showcase-multimodal-treatment-090000050.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "9b3e9e6e-b60b-3aab-82ae-77e645cf2bf1",
      "content": {
        "id": "9b3e9e6e-b60b-3aab-82ae-77e645cf2bf1",
        "contentType": "STORY",
        "title": "Allergan Aesthetics to Showcase Multimodal Treatment Approach and Continued Commitment to Skin Quality at AMWC Dubai",
        "description": "",
        "summary": "Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is set to present comprehensive AA Signature™ multimodal treatment approach to global audience, at the upcoming Internationally recognized Aesthetic Anti-Aging Medicine World Congress (AMWC), taking place in Dubai from Wednesday 1 – Friday 3 October 2025.",
        "pubDate": "2025-09-25T09:00:00Z",
        "displayTime": "2025-09-25T09:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/4591e97f9fa119e687b86928935135e7",
          "originalWidth": 400,
          "originalHeight": 97,
          "caption": "Allergan Aesthetics Logo (PRNewsfoto/AbbVie)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/2jrE9cZe71f03h9NEZ6N7g--~B/aD05Nzt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/4591e97f9fa119e687b86928935135e7.cf.webp",
              "width": 400,
              "height": 97,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6g_DEIvvGz3NoO_j.dWp7Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/4591e97f9fa119e687b86928935135e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-showcase-multimodal-treatment-090000050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/allergan-aesthetics-showcase-multimodal-treatment-090000050.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-09-25T08:44:00+00:00",
    "headline": "Where Will AbbVie Be in 5 Years?",
    "summary": "This big pharmaceutical company should be significantly bigger five years from now.",
    "url": "https://www.fool.com/investing/2025/09/25/where-will-abbvie-be-in-5-years/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "ed8f4394-edf1-33a2-bddd-aebbffb59f4e",
      "content": {
        "id": "ed8f4394-edf1-33a2-bddd-aebbffb59f4e",
        "contentType": "STORY",
        "title": "Where Will AbbVie Be in 5 Years?",
        "description": "",
        "summary": "This big pharmaceutical company should be significantly bigger five years from now.",
        "pubDate": "2025-09-25T08:44:00Z",
        "displayTime": "2025-09-25T08:44:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/62567cee84a2a0c2db4f4d900123880b",
          "originalWidth": 1400,
          "originalHeight": 787,
          "caption": "Three people wearing white lab coats with another person in a white lab coat in the background.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/s.p338d3Un0BAO7N5_0YYg--~B/aD03ODc7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/motleyfool.com/62567cee84a2a0c2db4f4d900123880b.cf.webp",
              "width": 1400,
              "height": 787,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_2Bk3AaPa0_sUTegFPhfbg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/62567cee84a2a0c2db4f4d900123880b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/09/25/where-will-abbvie-be-in-5-years/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/where-abbvie-5-years-084400209.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]